Sunovion Pharmaceuticals Inc.

Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for apomorphine sublingual film (APL-130277) to treat OFF episodes (the re-emergence or worsening of Parkinson’s symptoms otherwise controlled by medications) experienced by people living with Parkinson’s disease (PD). Read More »

Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease (PD).. Read More »

"This approval marks an important milestone for the mental health community in Canada, where few approved treatment options are available to adolescents with bipolar depression" Read More »

Sunovion Pharmaceuticals Inc. of Marlborough, Massachusetts recently gained approval for its supplemental new drug submission regarding Latuda (lurasidone HCI) — aimed at relieving adolescent schizophrenia — from Health Canada, potentially extending the treatment’s age range. Read More »

Sunovion Pharmaceuticals Inc.'s supplemental New Drug Application for a medication addressing bipolar conditions has won acceptance for review by the U.S. Food and Drug Administration. Read More »

The FDA says it is willing to look into and evaluate a drug that could help treat children who suffer from seizures. Read More »

Sunovion Pharmaceuticals Inc., five leading mental health advocacy organizations and singer, songwriter and mental health advocate Demi Lovato recently released "Beyond Silence," a documentary about their experience with speaking out for mental health. Read More »

Sunovion Pharmaceuticals' acquisition of Cynapsus Therapeutics has been finalized through Sunovion's subsidiary Sunovion CNS Development Canada. Read More »